483 related articles for article (PubMed ID: 16547501)
1. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Mitra SK; Lim ST; Chi A; Schlaepfer DD
Oncogene; 2006 Jul; 25(32):4429-40. PubMed ID: 16547501
[TBL] [Abstract][Full Text] [Related]
2. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
3. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
Mi Z; Guo H; Wai PY; Gao C; Kuo PC
Carcinogenesis; 2006 Jun; 27(6):1134-45. PubMed ID: 16474180
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors.
Mitra SK; Mikolon D; Molina JE; Hsia DA; Hanson DA; Chi A; Lim ST; Bernard-Trifilo JA; Ilic D; Stupack DG; Cheresh DA; Schlaepfer DD
Oncogene; 2006 Sep; 25(44):5969-84. PubMed ID: 16682956
[TBL] [Abstract][Full Text] [Related]
5. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
6. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
7. Tumor growth inhibition by synthetic and expressed siRNA targeting focal adhesion kinase.
Tsutsumi K; Kasaoka T; Park HM; Nishiyama H; Nakajima M; Honda T
Int J Oncol; 2008 Jul; 33(1):215-24. PubMed ID: 18575768
[TBL] [Abstract][Full Text] [Related]
8. Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation.
van Nimwegen MJ; Verkoeijen S; van Buren L; Burg D; van de Water B
Cancer Res; 2005 Jun; 65(11):4698-706. PubMed ID: 15930288
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
Kobayashi H; Gotoh J; Shinohara H; Moniwa N; Terao T
Thromb Haemost; 1994 Apr; 71(4):474-80. PubMed ID: 8052966
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice.
Ling X; Arlinghaus RB
Cancer Res; 2005 Apr; 65(7):2532-6. PubMed ID: 15805244
[TBL] [Abstract][Full Text] [Related]
11. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid priming potentiates the induction of urokinase-type plasminogen activator by cyclic adenosine monophosphate in mouse mammary carcinoma cells.
Mira-y-Lopez R
J Cell Physiol; 1991 Apr; 147(1):46-54. PubMed ID: 1645361
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.
Todaro LB; Ladeda V; Bal de Kier Joffé E; Farías EF
Oncol Rep; 2003; 10(3):725-32. PubMed ID: 12684650
[TBL] [Abstract][Full Text] [Related]
14. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
15. The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression.
Fayard B; Bianchi F; Dey J; Moreno E; Djaffer S; Hynes NE; Monard D
Cancer Res; 2009 Jul; 69(14):5690-8. PubMed ID: 19584287
[TBL] [Abstract][Full Text] [Related]
16. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
Frandsen TL; Holst-Hansen C; Nielsen BS; Christensen IJ; Nyengaard JR; Carmeliet P; Brünner N
Cancer Res; 2001 Jan; 61(2):532-7. PubMed ID: 11212246
[TBL] [Abstract][Full Text] [Related]
17. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Behmoaram E; Bijian K; Jie S; Xu Y; Darnel A; Bismar TA; Alaoui-Jamali MA
Am J Pathol; 2008 Nov; 173(5):1540-50. PubMed ID: 18832579
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.
Li XF; Yan PJ; Shao ZM
Oncogene; 2009 Nov; 28(44):3937-48. PubMed ID: 19701247
[TBL] [Abstract][Full Text] [Related]
19. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells.
Simeone AM; Nieves-Alicea R; McMurtry VC; Colella S; Krahe R; Tari AM
Int J Oncol; 2007 Apr; 30(4):785-92. PubMed ID: 17332916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
